|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 10/01/14 Novartis Bioventures Ltd SC 13D 4:275K Tokai Pharmaceuticals Inc RR Donnelley/FA Novartis AG |
Document/Exhibit Description Pages Size 1: SC 13D General Statement of Beneficial Ownership HTML 66K 2: EX-99.1 Miscellaneous Exhibit HTML 10K 3: EX-99.2 Miscellaneous Exhibit HTML 4K 4: EX-99.3 Miscellaneous Exhibit HTML 7K
| Schedule 13D |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
Tokai Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
(CUSIP Number)
General Counsel
Novartis Bioventures Ltd.
131 Front Street
Hamilton HM12, Bermuda
+1 441 298 1602
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨
| * | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13D
| CUSIP No. 88907J 107 | Page 2 of 10 Pages |
| 1. | Names of reporting persons
Novartis Bioventures Ltd. | |||||
| 2. | Check the appropriate box if a member of a group (a) ¨ (b) ¨
| |||||
| 3. | SEC use only
| |||||
| 4. | Source of funds (see instructions)
WC | |||||
| 5. | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
| |||||
| 6. | Citizenship or place of organization
Bermuda | |||||
| Number of shares beneficially owned by each reporting person with:
|
7. | Sole voting power
0 | ||||
| 8. | Shared voting power
4,644,328 | |||||
| 9. | Sole dispositive power
0 | |||||
| 10. | Shared dispositive power
4,644,328 | |||||
| 11. |
Aggregate amount beneficially owned by each reporting person
4,644,328 | |||||
| 12. | Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
| |||||
| 13. | Percent of class represented by amount in Row (11)
21.3% (1) | |||||
| 14. | Type of reporting person (see instructions)
CO | |||||
| (1) | The shares of Common Stock beneficially owned by Novartis Bioventures Ltd. and set forth in Row 11 represent 21.3% of the outstanding shares of Common Stock of the Issuer based on 21,841,742 shares of Common Stock outstanding as of September 22, 2014 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus dated September 16, 2014 (the “Final Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on September 17, 2014 pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended (the “Securities Act”). The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 972,000 shares of Common Stock within 30 days from the date of the Final Prospectus. |
SCHEDULE 13D
| CUSIP No. 88907J 107 | Page 3 of 10 Pages |
| 1. | Names of reporting persons
Novartis AG | |||||
| 2. | Check the appropriate box if a member of a group (a) ¨ (b) ¨
| |||||
| 3. | SEC use only
| |||||
| 4. | Source of funds (see instructions)
WC | |||||
| 5. | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
| |||||
| 6. | Citizenship or place of organization
Switzerland | |||||
| Number of shares beneficially owned by each reporting person with:
|
7. | Sole voting power
0 | ||||
| 8. | Shared voting power
4,644,328 | |||||
| 9. | Sole dispositive power
0 | |||||
| 10. | Shared dispositive power
4,644,328 | |||||
| 11. |
Aggregate amount beneficially owned by each reporting person
4,644,328 | |||||
| 12. | Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
| |||||
| 13. | Percent of class represented by amount in Row (11)
21.3% (1) | |||||
| 14. | Type of reporting person (see instructions)
CO | |||||
| (1) | The shares of Common Stock beneficially owned by Novartis AG and set forth in Row 11 represent 21.3% of the outstanding shares of Common Stock of the Issuer based on 21,841,742 shares of Common Stock outstanding as of September 22, 2014 upon the closing of the Issuer’s initial public offering, as reported in the Final Prospectus. The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 972,000 shares of Common Stock within 30 days from the date of the Final Prospectus. |
SCHEDULE 13D
| CUSIP No. 88907J 107 | Page 4 of 10 Pages |
| Item 1. | Security and Issuer. |
This statement on Schedule 13D (this “Schedule 13D”) relates to the common stock, par value $0.001 per share (the “Common Stock”), of Tokai Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”). The address of the Issuer’s principal executive office is One Broadway, 14th Floor, Cambridge, Massachusetts 02142.
| Item 2. | Identity and Background. |
(a) This Schedule 13D is being filed by Novartis Bioventures Ltd. (“NBV”) and Novartis AG (“Novartis”). NBV and Novartis are hereinafter sometimes collectively referred to as the “Reporting Persons.”
(b) The principal business address of NBV is 131 Front Street, Hamilton HM12 Bermuda, Mail: PO Box HM 2899, Hamilton HM LX, Bermuda. The principal business address of Novartis is Lichtstrasse 35, CH-4056 Basel, Switzerland.
(c) NBV is a company organized under the laws of Bermuda and is a wholly-owned indirect subsidiary of Novartis. NBV is a venture capital fund whose objective is to generate long-term capital gains for both entrepreneurs and investors. NBV’s principal business is investing in product- and platform-focused biotech, pharmaceutical and healthcare companies at all stages with an emphasis on the United States and Europe.
Novartis is a corporation organized under the laws of Switzerland and is the publicly owned parent of a multinational group of companies specializing in the research, development, manufacture, sale and distribution of innovative healthcare products. Novartis is the 100% indirect owner of NBV. Novartis provides healthcare solutions that address the evolving needs of patients and societies worldwide with a broad portfolio that includes innovative medicines, preventive vaccines, generic pharmaceuticals and consumer health products.
(d)-(e) Neither the Reporting Persons nor, to the best knowledge of each of them, any of the executive officers and members of the Board of Directors of each of the Reporting Persons set forth on Schedule I hereto during the last five years, (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f) The name, business address, present principal occupation or employment and citizenship of the executive officers and members of the Board of Directors of each of the Reporting Persons is set forth on Schedule I hereto and is incorporated herein by reference.
| Item 3. | Source and Amounts of Funds or Other Consideration. |
NBV acquired 45,223,369 shares of the Issuer’s Series D-1, Series D-2, Series D-3 and Series E preferred stock at various times between May 6, 2009 and September 16, 2014, the date the Issuer became a reporting company. Such shares of preferred stock automatically converted into 4,319,328 shares of Common Stock on a 10.47-for-one-basis upon the closing of the Issuer’s initial public offering without payment of consideration. NBV acquired 325,000 shares of Common Stock following the closing of the Issuer’s initial public offering at the public offering price of $15.00 per share.
The source of funds for the purchases of the Issuer’s securities was working capital of NBV.
| Item 4. | Purpose of Transaction. |
The information contained in Item 3 above is incorporated herein by reference.
All shares of Common Stock reported acquired by the Reporting Persons in this Schedule 13D were acquired for the purpose of investment and were not intended to and did not affect any change in the control of the Issuer.
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s shares of Common Stock in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the
SCHEDULE 13D
| CUSIP No. 88907J 107 | Page 5 of 10 Pages |
circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of the Common Stock or otherwise, they may acquire shares of Common Stock or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the shares of Common Stock currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions.
Except as described above, none of the Reporting Persons currently has any plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.
| Item 5. | Interest in Securities of the Issuer. |
(a) As of the date hereof, the Reporting Persons may be deemed, for purposes of Rule 13d-3 of the Act, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the shares of Common Stock described in Item 3 above. NBV is a wholly-owned indirect subsidiary of Novartis.
Based on 21,841,742 shares of Common Stock outstanding as of September 22, 2014 upon the closing of the Issuer’s initial public offering, as reported in the Final Prospectus, the Common Stock held by the Reporting Persons constitutes 21.3% of the outstanding shares of Common Stock of the Issuer. The number of shares of Common Stock outstanding does not give effect to the underwriters’ option to purchase up to an additional 972,000 shares of Common Stock within 30 days from the date of the Final Prospectus.
(b) With respect to the number of shares of Common Stock as to which each Reporting Person has:
(i) sole power to vote or to direct the vote with respect to such shares of Common Stock, please see row 7 of the applicable cover sheet to this Schedule 13D for such Reporting Person;
(ii) shared power to vote or to direct the vote with respect to such shares of Common Stock, please see row 8 of the applicable cover sheet to this Schedule 13D for such Reporting Person;
(iii) sole power to dispose or direct the disposition of such shares of Common Stock, please see row 9 of the applicable cover sheet to this Schedule 13D for such Reporting Person; and
(iv) shared power to dispose or to direct the disposition of such shares of Common Stock, please see row 10 of the applicable cover sheet to this Schedule 13D for such Reporting Person.
(c) Except as described above, during the past 60 days, there were no transactions in shares of Common Stock, or any securities directly or indirectly convertible into or exchangeable for shares of Common Stock, by either Reporting Person.
(d) Not applicable.
(e) Not applicable.
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer. |
There are no contracts, arrangements, understandings or relationships (legal or otherwise) among each Reporting Person and any other person or entities with respect to any securities of the Issuer, except for the following:
| • | Fifth Amended and Restated Investor Rights Agreement, dated as of May 13, 2013, among the Issuer, NBV and the other stockholders party thereto, pursuant to which, among other things, (i) NBV has the right to require the Issuer to register the shares of Common Stock held by it under the Securities Act under specified circumstances, (ii) NBV has incidental registration rights, subject to specified exceptions, if the Issuer proposes to file a registration statement to register any of its securities under the Securities Act, either for the Issuer’s own account or for the account of any of its stockholders, other than pursuant to the demand registration rights described in clause (i) and other than pursuant to a Form S-4 or Form S-8, and (iii) the Issuer is required to pay all registration expenses, including registration fees, printing expenses, fees and disbursements of the Issuer’s counsel and accountants and reasonable fees and disbursements of one counsel representing any selling stockholders, other than any underwriting discounts and commissions, related to any demand or incidental registration; and |
SCHEDULE 13D
| CUSIP No. 88907J 107 | Page 5 of 10 Pages |
| • | a lock-up agreement entered into by NBV in connection with the Issuer’s initial public offering pursuant to which NBV has agreed, for a period of 180 days after the initial public offering date set forth in the Final Prospectus, not to (i) offer, sell, pledge, contract to sell, purchase any option to sell, grant any option for the purchase of, lend, or otherwise dispose of, or require the Issuer to file with the SEC a registration statement under the Securities Act to register, any shares of the Issuer’s Common Stock or any securities convertible into, exercisable for or exchangeable for the Issuer’s Common Stock, whether any such transaction is to be settled by delivery of shares of the Issuer’s Common Stock or other securities, in cash or otherwise, or publicly disclose the intention to enter into any such transaction, or (ii) enter into any swap or other derivative transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of such shares of the Issuer’s Common Stock, whether any such transaction is to be settled by delivery of shares of the Issuer’s Common Stock or other securities, in cash or otherwise, or publicly disclose the intention to enter into any such transaction. |
| Item 7. | Material to be Filed as Exhibits. |
| Exhibit |
Description | |
| 1.1 | Form of Lock-Up Agreement entered into by and among the Issuer, the Representatives of the Underwriters and NBV (incorporated by reference to Exhibit A of Exhibit 1.1 of the Issuer’s registration statement on Form S-1/A (File No. 333-198052), filed on September 2, 2014) | |
| 10.1 | Form of Second Amended and Restated Registration Rights Agreement by and among the Issuer and the other parties thereto Fifth Amended and Restated Investor Rights Agreement, dated as of May 13, 2013, among the Issuer, the Reporting Person and the other stockholders party thereto (incorporated by reference to Exhibit 10.1 of the Issuer’s registration statement on Form S-1/A (File No. 333-198052), filed on September 2, 2014) | |
| 99.1 | Agreement regarding joint filing of Schedule 13D | |
| 99.2 | Evidence of Signature Authority | |
| 99.3 | Power of Attorney | |
SCHEDULE 13D
| CUSIP No. 88907J 107 | Page 7 of 10 Pages |
Signature
After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.
| Date: October 1, 2014 | NOVARTIS BIOVENTURES LTD. | |||||
| By: | /s/ Michael Jones | |||||
| Name: | Michael Jones | |||||
| Title: | Director | |||||
| By: | ||||||
| Name: | Laurieann Chaikowsky | |||||
| Title: | Authorised Signatory | |||||
| NOVARTIS AG | ||||||
| By: | /s/ Michael Jones | |||||
| Name: | Michael Jones | |||||
| Title: | Authorised Signatory | |||||
| By: | /s/ David Middleton | |||||
| Name: | David Middleton | |||||
| Title: | Authorised Signatory | |||||
SCHEDULE 13D
| CUSIP No. 88907J 107 | Page 8 of 10 Pages |
SCHEDULE I
DIRECTORS AND EXECUTIVE OFFICERS OF
NOVARTIS AG AND NOVARTIS BIOVENTURES LTD.
Directors and Executive Officers of Novartis AG
The name, address, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis AG are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual’s name refers to employment with Novartis AG and (ii) the business address of each director and executive officer of Novartis AG is Novartis Campus, Lichtstrasse 35, CH-4056, Basel, Switzerland.
| Name |
Relationship to Novartis AG |
Principal Occupation |
Citizenship | |||
| Joerg Reinhardt, Ph.D. | Chairman of the Board of Directors | Chairman of the Board of Directors | German | |||
| Ulrich Lehner, Ph.D. | Vice-Chairman of the Board of Directors | Member of Shareholders’ Committee of Henkel AG & Co. KGaA | German | |||
| Enrico Vanni, Ph.D. | Director | Independent Consultant | Swiss | |||
| Dimitri Azar, M.D., MBA | Director | Dean of the College of Medicine and Professor of Ophthalmology, Bioengineering and Pharmacology at the University of Illinois | American | |||
| Verena A. Briner, M.D. | Director | Professor of internal medicine at the University of Basel and Chief Medical Officer; Head of the Department of Medicine at the Lucerne Cantonal Hospital | Swiss | |||
| Srikant Datar, Ph.D. | Director | Arthur Lowes Dickinson Professor at the Graduate School of Business Administration at Harvard University | American | |||
| Ann Fudge | Director | Member of the Board of General Electric Company | American | |||
| Pierre Landolt, Ph.D. | Director | Chairman of the Sandoz Family Foundation | Swiss | |||
| Andreas von Planta, Ph.D. | Director | Partner at Lenz & Staehelin | Swiss | |||
| Charles L. Sawyers, M.D. | Director | Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center; Professor of Medicine and of Cell and Developmental Biology at the Weill Cornell Graduate School of Medical Sciences | American | |||
SCHEDULE 13D
| CUSIP No. 88907J 107 | Page 9 of 10 Pages |
| Name |
Relationship to Novartis AG |
Principal Occupation |
Citizenship | |||
| William T. Winters | Director | Chairman and CEO of Renshaw Bay, an alternative asset management and advisory company based in London | British | |||
| Joseph Jimenez | Member of the Executive Committee; Chief Executive Officer | Member of the Executive Committee, Chief Executive Officer | American | |||
| Steven Baert | Member of the Executive Committee; Head of Human Resources | Member of the Executive Committee, Head of Human Resources | Belgian | |||
| Felix Ehrat, Ph.D. | Member of the Executive Committee; General Counsel | Member of the Executive Committee; General Counsel | Swiss | |||
| David Epstein | Member of the Executive Committee; Head of Novartis Pharmaceuticals Division | Member of the Executive Committee; Head of Novartis Pharmaceuticals Division | American | |||
| Mark C. Fishman, M.D. | Member of the Executive Committee; President of the Novartis Institutes for BioMedical Research | Member of the Executive Committee; President of the Novartis Institutes for BioMedical Research; 250 Massachusetts Avenue |
American | |||
| Richard Francis | Member of the Executive Committee; Head of Sandoz Division | Member of the Executive Committee; Head of Sandoz Division | British | |||
| Jeff George | Member of the Executive Committee; Head of Alcon Division | Member of the Executive Committee; Head of Alcon Division; 6201 South Freeway Fort Worth, TX 76134, USA | American | |||
| George Gunn, MRCVS | Member of the Executive Committee; Head of Novartis Animal Health Division | Member of the Executive Committee; Head of Novartis Animal Health Division | British | |||
| Harry Kirsch | Member of the Executive Committee; Chief Financial Officer | Member of the Executive Committee; Chief Financial Officer | German | |||
| Brian McNamara | Member of the Executive Committee; Head of Novartis OTC Division | Member of the Executive Committee; Head of Novartis OTC Division; 200 Kimball Drive Parsippany, NJ 07054-0622, USA | American | |||
SCHEDULE 13D
| CUSIP No. 88907J 107 | Page 10 of 10 Pages |
| Name |
Relationship to Novartis AG |
Principal Occupation |
Citizenship | |||
| Andrin Oswald | Member of the Executive Committee; Head of Vaccines Division | Member of the Executive Committee; Head of Vaccines Division; 350 Massachusetts Avenue, Cambridge, MA 02139, USA | Swiss | |||
| André Wyss | Member of the Executive Committee; Head of Novartis Business Services | Member of the Executive Committee; Head of Novartis Business Services | Swiss | |||
Directors and Officers of Novartis Bioventures Ltd.
The name, address, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis Bioventures Ltd. are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite an individual’s name refers to employment with Novartis Bioventures Ltd. and (ii) the business address of each director and executive officer of Novartis Bioventures Ltd. is 131 Front Street, Hamilton HM12, Bermuda.
| Name |
Relationship to Novartis Bioventures Ltd. |
Principal Occupation |
Citizenship | |||
| Francis A. Waldvogel, M.D. | Chairman of the Board of Directors | Chairman of the Novartis Venture Funds Advisory Board | Swiss | |||
| Henri Simon Zivi | Deputy Chairman of the Board of Directors | General Manager of Novartis International Pharmaceutical Ltd. | Swiss | |||
| Michael Jones | Director | General Counsel of Novartis International Pharmaceutical Ltd. | British | |||
| Timothy Faries | Director | Partner at Appleby; Canon’s Court, 22 Victoria Street, PO Box HM 1179, Hamilton HM EX, Bermuda | British | |||
| This ‘SC 13D’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 10/1/14 | |||
| 9/22/14 | 3, 4, 8-K | |||
| 9/17/14 | 4, FWP, S-1MEF | |||
| 9/16/14 | 3, S-1MEF | |||
| 9/2/14 | S-1/A | |||
| 5/13/13 | ||||
| 5/6/09 | D | |||
| List all Filings | ||||